Publications by authors named "T Van den Broeck"
Background And Objective: Clinical practice guidelines for prostate cancer (PCa) are a valuable resource for everyday clinical practice. The clinical practice guidelines and recommendations produced by various societies should demonstrate a considerable level of consistency in terms of quality, regardless of the society that developed these given the common evidence base. However, to date, no study has assessed the quality of PCa clinical practice guidelines.
View Article and Find Full Text PDFBackground And Objective: The tumor microenvironment (TME) in non-muscle-invasive bladder cancer (NMIBC) plays an important role in the anticancer response. We aimed to identify the prognostic biomarkers in the TME of patients with NMIBC for progression to ≥T2.
Methods: From our institutional database, 40 patients with T1 high-risk NMIBC who progressed were pair matched for Club Urologico Español de Tratamiento Oncologico (CUETO) progression variables with 80 patients who never progressed despite longer follow-up.
Article Synopsis
- The 2024 guidelines for treating relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated by several European medical associations based on new research from 2020 to 2023.
- The updated guidelines include risk stratification to help determine salvage therapy options and highlight new treatment options like ARTAs, PARP inhibitors, and prostate-specific membrane antigen-based therapy.
- These guidelines emphasize the need for a multidisciplinary approach to PCa management and are updated annually to reflect the latest evidence, with the full details available online.
Background And Objective: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa). This paper aims to present a summary of the 2024 version of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on the screening, diagnosis, and treatment of clinically localised PCa.
Methods: The panel performed a literature review of all new data published in English, covering the time frame between May 2020 and 2023.